Physician profile
Lance I Austein
NPI 1366430969
$13,528.15
in general payments reported to CMS, 2019-2025
49 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,202 · 2020: $1,669 · 2021: $2,246 · 2022: $1,537 · 2023: $1,619 · 2024: $1,793 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,595.89 |
| Education | $277.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $2,091.83 | 2019-2025 | Zubsolv |
| Incyte Corporation | $1,509.84 | 2019-2025 | Jakafi, Jakafi |
| Abbvie INC. | $1,324.17 | 2019-2024 | Mavyret, Vraylar, Ubrelvy |
| Alkermes, INC. | $1,116.96 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Lilly USA, LLC | $756.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $635.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $560.20 | 2019-2025 | |
| Amgen INC. | $477.27 | 2019-2025 | Repatha |
| Novo Nordisk INC | $402.08 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Almatica Pharma LLC | $380.59 | 2021-2025 | Loreev Xr, Teriparatide, Gralise |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.54 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $336.92 | 2019-2025 | Trelegy Ellipta |
| Indivior INC. | $328.50 | 2019-2025 | Sublocade |
| Astellas Pharma US INC | $315.84 | 2019-2024 | Veozah |
| Collegium Pharmaceutical, INC. | $240.97 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Austein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.